Compare Organon & Co. Common Stock (OGN) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Veritone Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Veritone Inc trades at $0.53 (market cap $59.95M). The key difference: Organon & Co. Common Stock is far larger — about 60.4× Veritone Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Veritone Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Veritone Inc for 13 Days on average.
| OGN | VERI | |
|---|---|---|
Market Cap | $3.62B | $59.95M |
Volume | 2,892,999 | 2,880,267 |
Sector | Health | Technology |
52-Week High | $13.81 | $8.39 |
52-Week Low | $5.70 | $0.53 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $11.04B | $95.34M |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Veritone (VERI) trades at $0.59, down 2.64% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of $111.73M on $92.19M revenue in 2025, with negative cash flow from operations. Recent news includes a $15M equity offering and partnerships like the ATP Media deal, while facing a securities class action investigation.
The outlook remains challenged by persistent losses and cash burn, though analyst consensus is a Buy with a $3.75 price target. Key risks include execution on cost reductions, competitive pressures in AI, and legal overhangs. Upside hinges on revenue acceleration and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
